Other

Total cash equivalents and marketable securities, Gross Unrealized Gains

Vertex Pharmaceuticals Total cash equivalents and marketable securities, Gross Unrealized Gains decreased by 61.9% to $16.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 48.0%, from $32.50M to $16.90M. Over 2 years (FY 2023 to FY 2025), Total cash equivalents and marketable securities, Gross Unrealized Gains shows an upward trend with a 66.9% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_cash_equivalents_debt_and_equity_securities_unreal_5aaf42

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$15.90M$6.20M$3.70M$66.80M$22.80M$32.50M$41.00M$45.10M$44.30M$16.90M
QoQ Change—-61.0%-40.3%>999%-65.9%+42.5%+26.2%+10.0%-1.8%-61.9%
YoY Change————+43.4%+424.2%>999%-32.5%+94.3%-48.0%
Range$3.70M – $66.80M
CAGR+2.7%
Avg YoY Growth+248.3%
Median YoY Growth+68.8%
Current Streak2 quarters decline

Frequently Asked Questions

What is Vertex Pharmaceuticals's total cash equivalents and marketable securities, gross unrealized gains?
Vertex Pharmaceuticals (VRTX) reported total cash equivalents and marketable securities, gross unrealized gains of $16.90M in Q1 2026.
How has Vertex Pharmaceuticals's total cash equivalents and marketable securities, gross unrealized gains changed year-over-year?
Vertex Pharmaceuticals's total cash equivalents and marketable securities, gross unrealized gains decreased by 48.0% year-over-year, from $32.50M to $16.90M.
What is the long-term trend for Vertex Pharmaceuticals's total cash equivalents and marketable securities, gross unrealized gains?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's total cash equivalents and marketable securities, gross unrealized gains has grown at a 66.9% compound annual growth rate (CAGR), from $15.90M to $44.30M.